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Necrotising fasciitis (NF) is a rare, but potentially fatal, soft tissue infection. Described since classical 
times, historical depictions of the disease can mainly be found from wartime reports following battle 
injuries. Although a number of different species of bacteria have been implicated in the aetiology, 
perhaps the most well known is group A Streptococcus (GAS).  Infection control, early surgical 
debridement and antibiotic therapy are now the central tenets of the clinical management of necrotising 
fasciitis; these treatment modalities all have their roots in wars occurring during the last 150 years. We 
review reports from the 19th century, early 20th century and mid-20th century onwards, to show how the 
management of necrotising fasciitis has evolved in parallel with prevailing scientific thought and 
medical practice.   Historically, NF has often, but not exclusively, been associated with penetrating 
trauma, however, more recently along with a global increase in invasive GAS disease, reports have 
cited cases following non-combat related injuries or in the absence of antecedent events. We also 
examine the specific association between GAS necrotising fasciitis and trauma. In the 21st century, 
molecular biology has improved our understanding of GAS pathogenesis, but has not yet impacted on 
attributable mortality. 
 
Search strategy and selection criteria 
 
References for this review were identified through searches of PubMed for the following words 
“necrotising fasciitis”, “hospital gangrene”, “group A streptococcus”, “Streptococcus pyogenes”, 
“Goldsmith”, “bromine”, “Eagle effect”, “bear claw” and “trauma”. Articles not obtained through 
Pubmed were identified through searches in Google Scholar, Imperial College or British Library. 
Articles resulting from those searches and relevant references cited in those articles were reviewed. 
Articles were published in English, French or German. 
 
Word count: 5293 excluding abstract and figures/tables/references 
  
Introduction  
Phagedena, hospital gangrene, haemolytic streptococcal gangrene and, more recently, the “flesh-
eating” disease form a collection of terms used to describe what we now call necrotising fasciitis (NF).1 
Although the aetiology of NF is often polymicrobial, the Gram-positive bacterium Streptococcus 
pyogenes, also known as group A Streptococcus (GAS), is historically most associated with NF, in part 
due to it being implicated in the first large NF case series described.2 The original term “necrotising 
fasciitis” was suggested by Wilson in 1952, based on the pathology observed; a rapidly progressing 
infection that consistently resulted in fascial necrosis. 3 Despite its varied nomenclature, this potentially 
life threatening soft tissue infection is easily recognised in historical reports.  
 
Hippocrates described the association between a necrotising soft tissue infection and injury in the 5th 
century BC: “Many were attacked by the erysipelas… when the exciting cause was a trivial accident or 
a very small wound…  the erysipelas would quickly spread wisely in all directions… Flesh, sinews, and 
bones fell away in large quantities…”4 Subsequently, there are numerous conditions consistent with 
NF in the literature (Figure 1A), with particular reference to traumatic wounds acquired during 
wartime.5-7 The American Civil War in the late 19th century influenced the epidemiology and 
management of NF (Figure 1B), with detailed descriptions of hospital gangrene8 and a trial of bromine 
antisepsis for this condition.9 Around the same time, the field of Microbiology was developing and, in 
1874, the name Streptococcus was proposed for the organisms isolated from wound infections.10 The 
two World Wars and the intervening period improved our understanding of streptococci and NF, and 
emphasised the importance of surgery.2,11,12 Meanwhile, the Second World War stimulated large scale 
antibiotic production, representing a major transition in management of combat-related wounds.13,14   
 
At the end of the 20th century, increased NF incidence was reported in some countries.15  In particular, 
there was a worldwide increase in reporting of severe NF due to GAS.16-20 Although GAS NF is rare 
(UK incidence 2.1 per 1000,000), recent case fatality rates vary from 13 to 31%,21-24 and may rise to 
over 40% when associated with streptococcal toxic shock syndrome (STSS).25 This morbidity 
prompted the introduction of antibiotics targeted at toxin production and also the use of adjunctive 
intravenous immunoglobulin. Notable in the modern literature are reports of the NF following non-
penetrating, minor injury such as muscle contusion,26-33 in contrast to historical reports, which were 
ostensibly linked to penetrating injury typified by combat wounds. 4,8,11,34,35 
 
In this report, we predominantly focus on GAS NF and use historical data to review how the 
management of NF has evolved during three distinct periods: the late 19th century; the early 20th 
century and after the Second World War, leading to the multi-faceted approach used today. We also 
examine the association between blunt or penetrating trauma and GAS NF. Whilst reporting bias 
during wartime may in part account for the association between trauma and NF, there is also evidence 
from the peacetime literature supporting this association. As the term NF was only conceived in 1952, 
we will focus on conditions that have descriptive similarities with NF in the literature. In the 21st 
century, there is hope that modern scientific techniques to understand underlying pathophysiology will 
further refine management of this devastating disease process. 
 
Late 19th century - hospital gangrene, infection control and the Streptococcus 
Miasmas and laudable pus 
Hippocrates (5th century BC) and Galen (2nd century CE) greatly influenced medical practice in Europe 
up to the 19th century.  Prior to the 19th century, infectious disease was assumed to be from miasmas, 
poisonous vapours emanating from decomposing organic matter that contaminated the air.  
Furthermore, Hippocrates believed that disease susceptibility was related to an imbalance of four 
bodily fluids or “humours”. Galen proposed that pus expelled from wounds rebalanced the humours, 
“pus bonum et laudabile”, and was beneficial to the patient.36 Unfortunately, this was interpreted as pus 
being necessary for wound healing, and pus formation was actively encouraged. Thick, creamy 
“laudable” pus, (most probably Staphylococcus infection), was encouraged and distinguished from 
thin, watery pus, (most likely Streptococcus or Gram-negative infection), associated with mortality.  
The erroneous concept of “laudable” pus was not refuted until the second half of the 19th century with 
the introduction of antisepsis by Joseph Lister.37  
 
The American Civil War and hospital gangrene 
An estimated 700,000 soldiers died during the American Civil War from 1861 to 1865,8 the bloodiest 
war in US history.38 However, only one third of deaths were directly related to battlefield trauma, 
whilst the remainder were due to infectious diseases such as typhoid, dysentery and yellow fever.39 Of 
253,142 wounds reported in the permanent registers of the US Surgeon General’s office, 59,376 (23%) 
were flesh wounds which included hospital gangrene.38 Whilst hospital gangrene has been attributed to 
S.pyogenes, the aetiology is difficult to prove without historical specimens and, certainly, other 
organisms could also have been involved.  
 
Jones and infection control 
Joseph Jones, a Confederate Army surgeon, described vividly the rapid progression of hospital 
gangrene8 and the effect on the underlying tissues;  “……a purple or blue spot is first perceived…I 
have seen the skin in the affected spot melt away in twenty-four hours into a greyish and greenish 
slough, whilst a deep blue and purple, almost black areola, surrounding the dead mass, spread rapidly 
in ever increasing circles…Hospital gangrene destroys the cellular and adipose tissues most rapidly; 
the muscles, nerves, large blood-vessels, and the bones resist its action for a greater length of time.” 
Although French and British naval surgeons recognised hospital gangrene before the American Civil 
War,1 Jones’ depiction has been credited as the first modern description of NF.40 Whilst skin 
discolouration is a late feature of GAS NF, this description is compatible with cutaneous anthrax and 
clostridial necrosis and thus, whether Jones is describing GAS NF remains inconclusive. 
Jones believed in miasma theory and attributed the spread of hospital gangrene to “crowding together 
of sick and wounded soldiers in imperfectly ventilated and filthy hospitals…” which he felt led to 
favourable conditions for the  “…development of hospital gangrene upon reception of wounds.” 8 Jones 
recommended infection control measures to tackle hospital gangrene and observed that “the wounded 
should never be placed in wards with patients suffering from anyone of the contagious or infectious 
diseases… erysipelas, pyaemia, or hospital gangrene; and these various diseases should not be 
indiscriminately mixed together.”   
Goldsmith and bromine 
Middleton Goldsmith was a Union surgeon in Louisville, Kentucky during the American Civil War.  
He was struck by the high mortality associated with hospital gangrene and rapid spread on wards. He 
believed the condition occurred spontaneously “where the wounded are crowded together – where the 
wards are filled with the stench of traumatic profluvia, and receive the air of sewers and cellars”.9 He 
postulated that epidemics were linked, and that controlling them should reduce mortality. He reviewed 
various treatments including corrosive acids and caustic alkalis, which prevented tissue spread of 
gangrene, but destroyed remaining viable tissue and were only applicable to open wounds. 9 He 
became interested in halogens like chlorine, fluorine and bromine after noticing better recovery of 
patients on wards where bromine deodorants were being used as disinfectants.39  
 
Goldsmith recommended surgical debridement for hospital gangrene followed by bromine injections 
into muscle layers and exposed surfaces. He followed disease progression through the wound’s odour.  
He undertook a trial of bromine therapy in 334 cases of hospital gangrene, 304 of which received 
bromine either alone or after other treatments (Figure 2).  Eight patients who received bromine died 
(2.65% mortality) in comparison to patients treated with nitric acid (61.5% mortality) or other remedies 
(38.5% mortality).9 In comparison, previous treatments which included lead salts, caustic potash or 
nitric or carbolic acid yielded mortality rates of around 25 per cent, 35,41 whilst cumulative mortality 
from hospital gangrene was 45.6%. 38 His work acknowledged the importance of infection control 
through antisepsis in wound infection management.  
 
Germ theory and rise of the Streptococcus  
In the late 19th century, whilst America was being reconstructed after the Civil War, the field of 
Microbiology was developing in Europe.  It was during this time that the Streptococcus was recognised 
as a cause of disease.  The scientific community was attempting to determine the cause of suppurative 
infections.  Research often involved inoculating samples from affected individuals (animal or human) 
into other animals to observe disease progression.  One proponent was Robert Koch, who in 1876, 
whilst investigating the aetiology of traumatic infective diseases, isolated the anthrax bacillus, thus 
proving the germ theory of disease and beginning the “golden age” of bacteriology. 42,43  
 
In 1868, German surgeon Theodor Billroth isolated chain-forming bacteria from wound pus and named 
them Streptococcus (Greek: strepto – chain, and kokkus – berry).10 Eleven years later, Louis Pasteur in 
France isolated a chain-forming coccus from the blood and uterus of a woman with puerperal fever, 
attributing the disease to microorganisms invading the wounded uterine surface following childbirth. 44 
In 1882, another German surgeon, Friedrich Fehleisen, cultured streptococci from the skin of patients 
with erysipelas and reproduced signs of erysipelas following inoculation into humans, thus confirming 
an association between streptococcus and erysipelas.45,46 Two years later, the German physician, 
Friedrich Julius Rosenbach isolated streptococci from pus of an infected wound and named it 
Streptococcus pyogenes (Greek: pyon – pus, genein – to produce). 47 He believed this was separate 
from erysipelas-associated streptococci, a controversy only resolved with improved identification 
techniques,48 and publication by Rebecca Lancefield in 1933, of a streptococcal classification system 
based on carbohydrate composition of bacterial cell wall antigens: S.pyogenes was classified as group 
A Streptococcus.49 
 
The 19th century ended with the miasma theory being superseded by the germ theory, and a better 
understanding of gangrene associated with penetrating wounds. With this paradigm shift, the 
management of infectious diseases evolved.  Whilst limiting the spread to others through infection 
control had been the focus of Middleton’s trial of bromine,9 there was now a microbiological rationale 
for these measures.  However, it was not until the 20th century that the management of hospital 
gangrene became directed at infection eradication, through surgical advances and antibiotic discovery.  
 
Early 20th century – the surgeon’s scalpel and the antibiotic chemists 
“Prior to the war, the surgeon gave most of his attention to aseptic methods, his great object being to 
exclude microbes from the wound. The question of how to deal with the bacteria after they were in 
possession was a problem of much less interest to him.”34 
 
Although the term NF was not coined until after the Second World War, several NF-like clinical 
syndromes were described in the early 20th century in association with traumatic processes including 
childbirth, burns and penetrating war-wounds (Table 1). Barrier nursing and infection control, 
antimicrobial treatment and effective debridement of necrotic tissue are consistent themes in the 
literature from this period (Table 1).  Whilst infection control was rooted in the hospital gangrene 
pioneers of the 19th century, much of modern NF management has its basis in work that occurred 
during the World Wars. 
 
 
Streptococci and wounds during the First World War 
The Scottish physician-scientist, Alexander Fleming, eloquently described the predominance of 
streptococci in war wounds in 1915.11 Whilst stationed in France with the Royal Army Medical Corps, 
he studied the bacterial flora of over 200 wounds and described a transition between early stage 
infections, which contained anaerobic organisms, to late stage infections containing mainly pyogenic 
cocci (Figure 3A and 3B). Penetrating traumatic wounds contained streptococci and he implicated 
short-chained streptococci in the development of gangrene.  Additionally, blood cultures from febrile 
wounded soldiers isolated Streptococcus. Fleming thus observed, “streptococcus is without doubt the 
most important member of this group as regards infection of wounds.” His management was to not rely 
on antiseptics alone, as they did not penetrate into deep tissues.  He encouraged irrigation with 
hypertonic saline34 and emphasised surgical debridement; “…if it were possible for the surgeon to 
remove completely the dead tissue I am quite sure the infections would sink into insignificance.” 11 
 
Dakin, Depage, debridement and delayed primary closure 
During the First World War, surgical techniques were refined to manage infected wounds. The 
pioneering French military vascular surgeon, Alexis Carrel, and biochemist Henry Dakin devised a 
wound care technique utilising a chlorine-based disinfectant, “Dakin’s solution”, and rubber “Carrel” 
tubes for wound irrigation.56  Belgian surgeon Antoine DePage proposed that Dakin’s solution was 
introduced following tissue debridement, excision of contaminated tissue, and epluchage, “peeling” of 
wounds before dressing.57 Depage then advocated delayed primary wound closure depending on the 
bacteriology and observed that “for streptococci infection never to suture but to submit the wound to 
adequate treatment…to wait until the streptococci had disappeared, or had become attenuated 
sufficiently to permit primary union”.57 He has been credited with making the most important 
contribution to wartime surgery of any war. 58 
 
Meleney, gangrene and bear claw fasciotomy 
In 1924, Frank Meleney, an American missionary surgeon working in China, reported an outbreak of 
20 cases of haemolytic streptococcal gangrene in a Peking hospital, with a mortality of 20%, and 
illustrated that surgery is vital to reduce mortality.2,12 Meleney observed that gangrene was caused 
either by anaerobic bacteria or haemolytic streptococci.  He noted that the “infection usually starts from 
a superficial break in the skin, a scratch, a hypodermic injection, a cut, a pimple or a boil but 
occasionally develops without any point of origin,” implying that penetrating trauma is not a 
prerequisite for NF.  Meleney successfully treated cases with “bear-claw scratch” debridement,2,12 
building on the work of the First World War surgeons.  In this method, single, long, incisions were 
made to the deep fascia on either side of the affected limb (similar to the appearance of a scratch from a 
“bear claw”), to just beyond the necrotic area.  Extending incisions too far would spread infection but, 
if done correctly, would negate the need for amputation.12 This technique was subsequently superseded 
in favour of more extensive fascial exposure and debridement. 59 
 
Prontosil rubrum and the sulphonamides - the antibiotic era begins 
In 1932, the German histopathologist and bacteriologist Gerhard Domagk observed that mice and 
rabbits treated with the red dye, prontosil rubrum, derived from sulphanilamide, survived lethal 
infections with haemolytic streptococci and staphylococci.60 He received the Nobel Prize for Medicine 
in 1939 for his work on the sulphonamides, which revolutionised the treatment of infected war wounds. 
Animal research highlighted the benefit of sulphonamides in preventing wound infections when 
sprinkled in the wound.51 Whilst deaths of the wounded in the US army was 8.26% in the First World 
War, this decreased to 4.5% in the Second World War during which American soldiers were issued 
sulphonamide powder in first aid packs, along with improved surgical techniques.52,61 Sulphonamide 
usage on wounds escalated from 1942, but rather than sprinkling, the drug was dumped in lumps on 
wounds, thereby reducing drug absorption.  Meanwhile, the importance of adequate wound 
debridement was neglected.  Wounds became infected, and thus it was misinterpreted that 
sulphonamide powder was detrimental to wounds.58 Leonard Colebrook, a contemporary of Fleming, 
also investigated the use of sulphonamides to treat puerperal sepsis,50,62 which is usually attributed to 
GAS and follows maternal tissue injury during childbirth.63 Colebrook successfully treated 38 patients 
with haemolytic streptococcal puerperal fever with sulphonamides, reducing mortality from 24.4% in 
1935 to 4.7% in 1936.50,64 
 
Penicillium rubrum and the push for penicillin 
After the First World War, Alexander Fleming had returned to work at St. Marys’ hospital in London 
and in 1929, he published a description of the antibacterial properties of penicillin, produced by the 
Penicillium rubrum mould.34 However, it was not until a decade later, at the start of the Second World 
War, that biochemist Ernst Chain and pathologist Howard Florey, along with colleagues Edward 
Abraham and Norman Heatley, working at the Dunn School of Pathology in Oxford were able to 
produce sufficient penicillin to undertake clinical trials.13 Florey, Chain and Fleming were awarded the 
1945 Nobel Prize for Medicine for their discovery.65  
 
Limited research funding led Florey and Heatley to the USA in June 1941, to gain the support of the 
American pharmaceutical industry.  Through improved deep fermentation techniques and isolation of 
Penicillium strains with higher penicillin yields, further clinical trials in military and civilian 
populations occurred and sufficient penicillin was produced to accompany troops for the D-Day 
landings.66 Penicillin use during the Second World War was clearly documented.67,68 British Army 
surgeons in Italy prevented wound infections by inoculating penicillin-sulphathiazole powder into 
wounds following debridement in field hospitals, however, there was “…no tendency on the part of 
surgeons to neglect surgery and rely too much on penicillin.”  Clearly, for traumatic battle wounds, 
surgery was the main priority, although a combination of surgery and penicillin was emphasised, 
“…for the knife alone cannot get rid of infection”.67,68	  	  	  
Infection control revisited – nosocomial GAS during the Second World War  
About a hundred years before the Second World War, Ignaz Semmelweiss demonstrated the 
importance of hand-washing in preventing puerperal sepsis.69	   	   During the Second World War, 
nosocomial transmission of GAS was a recognised problem.5 Thus, the role of infection control was 
revisited. Wards were reorganised to prevent patient-to-patient transmission and environmental 
sampling and cleaning practised.  Healthcare-workers were advised to clean hands and use masks and 
sterile instruments. A wound dressing technique was developed that included “clean” and “dirty” 
nurses.5,70 This was responsible for reducing GAS wound infection from 15.4% to 1.1% in one wartime 
neurosurgical unit.70  Many practices advocated during this time are still recommended for prevention 
of nosocomial transmission of GAS today.71 	  	  
Wilson and necrotising fasciitis 
In 1952, Dr Ben Wilson, a surgeon in Parkland Hospital, Dallas, coined the phrase “necrotising 
fasciitis”, which was adopted into widespread use.  He observed that fascial necrosis was a consistent 
manifestation in 22 cases admitted at the hospital from 1948 to 1951 and earlier cases in the literature.3 
He also observed that NF “…may start in an operative wound, in a trivial injury…or may appear 
spontaneously.” Of note, whilst haemolytic streptococci were cultured from all of Meleney’s cases, 12 
haemolytic bacteria were cultured in about half of Wilson’s cases, of which 88% were identified as 
Staphylococci.3 Furthermore, mortality in Wilson’s cohort was only 8.7% compared to 20% observed 
by Meleney. Wilson stressed the importance of early recognition, prompt surgery, penicillin and 
support for abnormal physiology. 3    
 
By the mid-20th century, infection control advocated by American Civil War surgeons, had been joined 
by antibiotics targeted at Streptococcus pyogenes and effective surgical debridement, as emphasised by 
Fleming, Meleney and Wilson in the battle against streptococcal gangrene.   Indeed, after the Second 
World War, there is a relative paucity of literature on GAS NF in conflicts in Korea, Vietnam and the 
Falklands, perhaps due to the measures described, leading to a decline in infections.  However, the 
effectiveness of penicillin was questioned, and the last two decades of the 20th century saw a global re-
emergence of invasive GAS infections.   
 
Late 20th century – the Eagle effect, immunoglobulins and hyperbaric oxygen  
The Eagle effect and antibiotics inhibiting toxin synthesis  
Penicillin represented a major transition point in the management of NF. However, in 1948, Harry 
Eagle described the “Eagle effect”, the paradoxical reduced antibacterial effect of penicillin against a 
variety of Staphylococcus and Streptococcus species when administered at high doses in vitro.72 GAS 
were not subject to this, and there have been no GAS isolates resistant to penicillin.73 However, 
treatment failure in spite of penicillin sensitivity and high mortality associated with severe disease, led 
to the hypothesis that when GAS reaches the stationary growth phase, as may occur rapidly with high 
innocula, there is reduced expression of penicillin-binding proteins and diminished susceptibility to 
beta-lactams.20,74 Eagle also demonstrated that delayed initiation of treatment with penicillin after 
infection with GAS, in a mouse model of myositis, led to an apparent reduction in bactericidal effect 
(Figure 4A).74 In the 1980s this latter “Eagle effect” was revisited comparing penicillin, erythromycin 
and clindamycin in an animal model of GAS myositis and, unlike penicillin, the efficacy of 
clindamycin was not adversely affected (Figure 4B).75  This supported clindamycin use for NF 
treatment (in combination with a penicillin), particularly when associated with toxic shock syndrome, 
as clindamycin inhibits toxin production.76  Retrospective clinical studies have been generally 
supportive of adjunctive clindamycin therapy in severe disease,77-79 however, recent outbreaks by 
clindamycin resistant GAS80 may limit the utility of this drug.  
 
Intravenous immunoglobulin and hyperbaric oxygen 
STSS has a high mortality and is associated with almost half of NF cases.17 Patients require supportive 
measures in a high dependency or intensive care setting. Additionally, intravenous pooled human 
immunoglobulin (IVIG) has been advocated. Bacterial toxins, acting as superantigens, lead to massive 
inflammatory cytokine release, tissue destruction and shock.81 Augmenting the humoral immune 
response with IVIG neutralises superantigens,82 enhances GAS clearance, and is anti-inflammatory.83   
IVIG is prepared from pooling immunoglobulin from blood donors, and due to variant CJD in the 
1990s, 84 its use is strictly controlled in the UK and elsewhere.   Studies assessing IVIG in severe 
invasive GAS disease are limited. One randomised, double-blind, placebo-controlled trial was 
underpowered to reach statistical significance due to the small numbers of patients recruited.85  
Retrospective reports are complicated by multiple confounding factors, including use of historical 
controls with higher mortality rates86 or children with less severe disease.87 A recent retrospective 
cohort analysis appeared to favour IVIG in severe invasive GAS, but was again underpowered.77  The 
sample size for clarifying the role of IVIG in this rare disease88 means that the definitive answer is not 
forthcoming.  
 
Another treatment modality tried in the late 20th century was hyperbaric oxygen therapy.  This 
adjunctive therapy is thought to increase tissue partial pressure of oxygen, increasing bacterial killing 
and facilitating wound healing.89 However, the few studies of hyperbaric oxygen therapy in GAS NF 
show little outcome benefit90-92 and transferring patients to a centre with hyperbaric oxygen therapy 
may delay effective surgical debridement.90,93 
 
Diagnostic delays 
Undoubtedly one of the most challenging aspects of GAS NF management remains diagnosis. 
Diagnostic delay is a common in historical and current literature2,32 and may result in adverse 
outcomes.32  The innocuous appearance of the infection, relationship to muscle contusion or attribution 
of pain to an injury may delay presentation or mislead clinicians.30,32 Skin discolouration, blistering, 
and visible necrosis described in the literature are late features of NF and are ominous signs.  Today, 
imaging and frozen sections with good histological examination may aid diagnosis, but intra-operative 
assessment and exploration is preferable when diagnostic uncertainty is present (reviewed in 94). 
 
Global GAS resurgence and non-penetrating trauma associated NF 
Since the 1980s, there has been a global resurgence of invasive GAS diseases, such as NF and STSS.95 
GAS is known to infect wounds where skin integrity has been broken,96 however,  blunt trauma leading 
to muscle contusion preceding GAS NF have been reported worldwide.26-32,97-99 Amongst larger studies 
of GAS NF from North America and the UK, non-penetrating trauma or injury was present in 
approximately 25% of NF,17,100-102 with a significant association between non-penetrating trauma and 
GAS NF, but not cellulitis, observed.103 Other predisposing factors include burns, surgery and varicella 
infection (Table 2). Varicella infections are commonly complicated by secondary bacterial infections, 
including NF104,105 and in countries with the varicella vaccine in children, there has been a reduction in 
paediatric cases of invasive GAS.106  
 
Generally, GAS NF affects more males than females, although whether this represents reporting bias is 
unclear.   There have also been cases of GAS NF with no obvious portal of entry. For example, from a 
cluster of six NF cases in the UK, two had no predisposing history.107 Other case series have also noted 
a similar lack of antecedent history, with no portal of entry in eight of 20 patients with invasive GAS 
infection in the USA,19 and five of 14 consecutive NF cases over five-years in Northern Australia.90 
Occasionally, patients reported mild upper respiratory tract infection.108 Diabetes, obesity and chronic 
alcohol use also predispose to NF.21,109,110 
 
The management of patients in these reports are similar; initial broad-spectrum antibiotics, rationalised 
to benzyl-penicillin and clindamycin, once GAS is identified.  Surgical debridement is always 
performed, with repeated intervention often necessary.   Mortality is high, in spite of intensive care 
support, and patients have long hospital stays and require long-term rehabilitation (Table 2). 
 
Invasive GAS and the modern military  
The global resurgence of GAS has also been documented specifically in military personnel.  Training 
facilities have seen outbreaks of the whole spectrum of GAS disease including pyoderma, ecthyma, NF 
and STSS, and post-infectious sequelae including rheumatic fever and glomerulonephritis.113-116 This 
morbidity amongst military cohorts has been attributed to crowded conditions, reduced hygiene and a 
lack of type specific immunity.  Consequently, the US military has used prophylactic penicillin, or 
macrolides in penicillin allergy, in basic military trainees since 1953.117-119  
 
Necrotising fasciitis due to other pathogens 
Historically, GAS was the predominant organism recognised in NF, however, widespread antibiotic 
therapy and better bacterial identification, has meant that penetrating traumatic wound infections are 
frequently polymicrobial or contain resistant organisms. A recent review updated an earlier 
classification120 and divided NF into four aetiological types: polymicrobial NF (type I) being 
distinguished from monomicrobial NF caused by Gram positive (type II) or Gram negative bacteria 
(type III) or fungi (type IV).121 Whilst some recent case series report polymicrobial aetiology being 
more common,109,122,123 others report single pathogens more commonly isolated,124-126 although 
limitations in culture methods may influence this.124   Methicillin resistant Staphylococcus aureus, 
Klebsiella pneumoniae, Pseudomonas aeruginosa, Vibrio parahaemlyticus and Actineobacter 
baumanii have all been isolated, with the predominant organism depending on geography.35,124-128  
 
One form of polymicrobial NF is Fournier’s gangrene, a necrotising perineal and genital infection first 
described in healthy young men by venereologist Jean-Alfred Founier in 1883. He also noted the 
association of gangrene with diabetes, alcoholism and urological trauma.129  Organisms in Fournier’s 
gangrene are usually commensals, with aerobic and anaerobic bacteria acting synergistically, through 
mutually beneficial nutrient and toxin production.130 Widespread antibiotic use has led to bacterial 
resistance, necessitating the use of broad spectrum antibiotics at the outset.131      
 
Gas gangrene not caused by GAS  
No historical review of NF would be complete without mentioning the ubiquitous Gram–positive 
anaerobic bacteria, the Clostridium species.  Gas gangrene also known as “clostridial myonecrosis” has 
been associated with soil containing Clostridium which contaminate battlefield wounds from 
penetrating injury. Estimates of gas gangrene during the First World War are approximately 10% but 
less than 1% in the Second World War.132 Although advances in weaponry led to tissue destruction 
favouring anaerobic growth, improved surgical techniques including debridement and delayed primary 
closure led to a decrease in mortality from this condition.133 Historically, C. perfringens is most 
associated with necrotising infections due to penetrating trauma, however, recently C. septicum and C. 
sordellii have also been implicated in infection at sites of minor injury.134 
 
Into the 21st century – molecular pathogenesis of GAS NF 
The development of molecular biology over the last 40 years has enabled a better understanding of the 
mechanisms by which GAS cause disease. GAS is a human specific pathogen and must first colonise 
the host, usually the nasopharynx or skin. Following colonisation, immune evasion is a prerequisite for 
bacterial invasion and establishment of deep tissue infection.  It is here that molecular biology has 
improved our understanding of GAS NF pathogenesis, with some mechanisms described below (Figure 
5).  Whilst not exhaustive, it illustrates our current understanding of the intricacies of host-pathogen 
interactions leading to NF. 
 
Bacterial virulence factors in NF 
GAS expresses several virulence factors to evade humoral immune effectors.136,139-141,144  The best-
studied GAS virulence determinant is the M protein and although there are over 100 M-serotypes, M1 
and M3 isolates predominate in invasive disease.145,146 This predominance is likely related to virulence 
genes carried by these M-types, coupled with serotype-specific ability to evade the immune response.  
Through its interaction with host immune proteins, the M protein itself may help invading bacteria. 
Additionally, some  NF pathophysiology may be explicable by M protein binding fibrinogen, initiating 
a cascade resulting in vascular leakage and toxic shock.147 
 
GAS has several mechanisms to evade neutrophils, a key player in host innate immunity, such as the 
hyaluronic acid capsule, streptolysins and DNAses.140,148,149 GAS expresses the protease SpyCEP, 
which cleaves the chemokine Interleukin-8 that is involved in recruitment and activation of neutrophils, 
142 perhaps explaining the paucity of neutrophil infiltrates in histopathological sections from severe NF.   
SpyCEP enables survival and dissemination of GAS,150 while high levels of SpyCEP activity correlated 
with increased disease severity and poor clinical outcome.142 Other GAS proteases are implicated in 
immune evasion and the pathology seen in NF.136,138,141 Notably, the cysteine protease, SpeB, may be 
involved in tissue necrosis138 and also in phenotypic switching of bacteria during invasive infection.137 
Genetic reasons behind the aggressive phenotype of NF-causing GAS isolates are also being 
determined.  For example, mutations in the CovR/S regulatory system, which enables the bacterium to 
respond to its environment, occur readily in M1 isolates. CovR/S mutations are associated with 
invasive bacterial phenotypes with reduced SpeB production and increased SpyCEP expression.142,143 
Furthermore, a single nucleotide polymorphism in the mtsR gene of certain M3 isolates, which encodes 
a transcriptional regulator, is associated with a reduced propensity to cause NF.151 Other virulence 
determinants have been implicated in NF pathogenesis, as well as unique mechanisms by which GAS 
is exquisitely adapted to its host.152 
 
Animal models of muscle injury and GAS  
To replicate the observation that GAS NF may occur with minor injury, mice inoculated with GAS 
were bruised at a site distant to the original inoculation.  The investigators observed increased mortality 
compared to unbruised controls, implying that distant muscle sites may harbour bacteria.153   
Furthermore, M1 and M3 GAS adhere to damaged skeletal muscle cells, possibly via cytoskeletal 
vimentin,154 and in a murine model, GAS seeded moderately damaged muscle, in association with 
vimentin upregulation, following non-penetrating injury.155  Although the studies were limited, the 




Our understanding of GAS molecular pathogenesis has sadly not yet had a profound effect on NF 
management.  Ultimately, molecular biology may lead to a GAS vaccine, which would prevent the 
whole GAS disease spectrum.   GAS vaccine development has a long, varied history and was discussed 
by Fleming in 1915.11  Inactivated whole cell vaccines were unsuccessful in the 1940s,156  whilst the M 
protein containing vaccines have only slowly advanced to clinical trials.157,158 Other vaccine targets 
include SpyCEP159 and C5a peptidase.160  As NF is rare, the success of vaccines at preventing GAS NF 
will be difficult to quantify and a surrogate of protection is needed. 
 
Conclusion 
The condition we now call necrotising fasciitis has existed since antiquity, and although its name has 
changed, it has consistently been associated with trauma.  The modern management of NF has evolved 
over the last 150 years as our understanding of the aetiology of this condition has changed, with many 
advances resulting from the management of war wounds.  Goldsmith’s bromine trials arose from the 
stench of the hospital wards of the American Civil War, even before bacteria causing NF had been 
isolated. Surgical intervention was emphasised by Alexander Fleming from war-torn France during the 
Great War, and reiterated by Frank Meleney during the interwar years.  The Second World War saw 
the use of sulphonamides to treat wound infections, and was the stimulus for mass production of 
penicillin. Infection control, effective debridement and broad-spectrum antibiotics remain the mainstay 
of the modern management of GAS NF.   
 
And yet despite postoperative supportive care on technologically-advanced intensive care wards, and 
adjunctive therapy such as IVIG and hyperbaric oxygen, the outcome from GAS NF remains 
depressingly high.  Mortality rates as high as 40%25 are almost twenty times worse than Goldsmith’s 
patients with hospital gangrene treated with bromine in 1863.9  It is the authors’ experience that a 
failure to recognise NF contributes to this ongoing high mortality. Why the mortality remains so high is 
unclear; although historical reporting bias may contribute, an alternative view is that GAS has become 
more virulent.19,20 Hopefully, developments in molecular biology will allow us to answer this question 
and also lead to improved disease prevention through an effective GAS vaccine, which would be the 
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Figure 1.  (A) Hospital gangrene affecting the hand following a lancet puncture of an abscess.  
Watercolour by William Alfred Delamotte, 1847. (B) Hospital gangrene of an arm stump, reproduced 
from plate XV in The medical and surgical history of the war of the rebellion, 1861-65 38. Images are 




 Figure 2 Results of the trial of bromine for the treatment of hospital gangrene undertaken by 
Middleton Goldsmith in Louisville, Kentucky during the American Civil War.  Table reproduced from 
A report on hospital gangrene, erysipelas and pyaemia: as observed in the departments of the Ohio 





Figure 3.  Analysis of bacteriological examination of a series of wounds undertaken by Alexander 
Fleming of the Royal Army Medical Corps whilst stationed in Boulogne, France during the First World 
War. (A) The different bacteria observed in wounds during three different stages, based on the days 
after infection.  Streptococci are present in all stages of infection. (B)  Drawing from films of pus taken 
from wounds showing the late stage of infection with pyogenic cocci, “wisp” bacilli and many pus 
cells. Reproduced from On the bacteriology of septic wounds. 11 
  
 Figure 4. The “Eagle effect” in an in vivo model of myositis  
(A) Eagle demonstrated in vivo the reduced bactericidal effect of delaying penicillin treatment. Mice 
were infected intramuscularly with 5x107 Streptococcus pyogenes, divided into groups (0, 1.5, 3, 6, 9 
hours) and treated with procaine penicillin (0.15cc of suspension at 10,000units/cc).  Each point 
represents the median number of organisms recovered from infected muscle tissue.  The mortality of 
the animals increases as treatment is delayed. He suggested that the reduced activity of penicillin in 
older infections is not due solely to the large number of organisms, but due to the likely physiological 
state of the bacteria and the host tissue environment. Reproduced from Experimental approach to the 
problem of treatment failure with penicillin. I. Group A streptococcal infection in mice. 74 
(B) The “Eagle effect” was later revisited by comparing penicillin, erthromycin and clindamycin in 
another mouse model of myositis.  When treatment was delayed to six hours post infection, mice 
treated with penicillin had a similar mortality to untreated control animals, whilst 80% of the 
clindamycin group survived. Reproduced from	   The Eagle effect revisited: efficacy of clindamycin, 
erythromycin, and penicillin in the treatment of streptococcal myositis. 75  
  
 
Figure 5. Bacterial virulence factors associated with invasive streptococcal disease. 
Streptococcus pyogenes possesses a number of virulence factors, which enable the bacteria to evade the 
host innate and adaptive immune defences and establish a deep tissue infection.  Surface expressed 
proteins such as the M protein and C5a peptidase are involved in complement evasion,135,136 whilst 
SpyCEP influences neutrophil activation and migration. The secreted protein SpeB is involved in the 
tissue necrosis in NF and phenotypic switching of bacteria in invasive infection.137,138 Other secreted 
proteins include; SIC that aids complement evasion,139 the DNAase Sda1 that acts on neutrophil-
derived extracellular traps,140 and the immunoglobulin degrading protein, IdeS.141  The two component 
regulatory system, CovR/S is involved in the regulation of some of these virulence factors and may be 
associated with more invasive bacterial phenotypes.142,143	  
Table 1.  Different patterns of injury or trauma leading to S. pyogenes gangrene and recommended management of these cases during the early 20th century 	   	  
Trauma or injury Geographical Location Presentation (number) and Aetiology Management  Reference 
Penetrating wounds due to 
explosives  
Boulogne, France Infected wounds (210) from penetrating trauma 
177/210 isolated streptococci  
 
Avoid antiseptics  
Irrigate wounds with hypertonic saline.  




Peking Union Medical 
College, China 
Haemolytic streptococcal gangrene (20).  
Additionally 7/17 blood cultures positive for 
haemolytic streptococcus 
Surgical debridement  
Hygiene and infection control measures.  
Wounds irrigated using Dakin solution  
2,12 
Puerperal Sepsis Queen Charlotte’s 
Hospital, London, UK 
Haemolytic streptococcal puerperal fever (38 
and 26 cases) 
36/38 and 25/26 group A Streptococcus  
Treatment with sulphonamides, (Prontosil) 
Effective Infection Control 
50,51 
Infected open wounds 
during Second World War 
France Haemolytic Streptococcus isolated from wound 
infections  
Dusting of wounds with sterile sulphonamide 
powder (American soldiers in a first aid kit) or 
given systemically  
52-54 
Patients with burns Glasgow Royal 
Infirmary, UK 
Infection contaminating burns (516) 
69/516 haemolytic Streptococcus 
Treatment in specialised burn units 
Cubicle isolation to minimise contamination  
Strict barrier nursing 









USA Limb Nil S.pyogenes Skin injury 100% Surgical debridement, 




















Debridement, iv penicillin, 
tobramycin, metronidazole 
99 




High dose benzylpenicillin, 
fasciotomy and debridement of 
thigh, ITU support 
29 
8 46 6 Male , 
2 
Female 
USA Limb 5/8 history of 
chronic illness 
S.pyogenes Blunt trauma, 
bee sting and 
ulcer 
25%  Surgical debridement, 6/8 
started on combination of 
clindamycin, penicillin or 
cephalosportin. 
98 
1 19  Male Germany Thigh Nil S.pyogenes Fall on side 0% Debridement, ITU support, 
antibiotic regimen not described 
27 
except for Candida sepsis with 
Diflucan 
1 36 Female Japan Right hip Nil S.pyogenes Injury to right 
hip 
100% Supportive care as arrived at 




Male USA Hand Rheumatoid arthritis 
(61 year old) 
S.pyogenes Blunt trauma 
to the hand 
50% Debridement, ITU support, 
clindamycin, penicillin and 
IVIG 
112 
1 42 Male UK Anterior 
chest Wall 





0% Ceftriaxone, flucloxacillin and 
metronidazole then changed to 
benzylpenicillin, ciprofloxacin 
and clindamycin (culture 
results) surgery and ITU support  
28 
1 46 Female France Hand/arm Nil S.pyogenes Contusion  0% Surgery and antibiotics not 
specified. 
31 
1 47 Male Germany Leg Likely NSAID 
injection 
S.pyogenes Minor trauma 
to left leg 
during tennis 
100% Surgical exploration and 
debridement, antibiotic 
treatment not mentioned  
30 





Serbia Chest wall, 
upper limb 
and trunk 
NSAIDs - naproxen, 
aspirin and 
diclofenac 
S.pyogenes Injury, Fall 100% Died on admission 97 
1 33 Male UK Hamstring Nil S.pyogenes Muscle strain 100% Surgical exploration and 
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